Final results from a Phase 2 trial of binimetinib in patients with advanced NRAS mutant melanoma were presented at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, Spain.
MRV Research
New cancer drug combination halts disease, extends life in advanced melanoma patients
A world-first study in today’s New England Journal of Medicine heralds the efficacy of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma.
Clinical practice guidelines for melanoma care have room for improvement
Adding a dedicated section for the identification, screening and follow-up of people at high risk for melanoma, in addition to providing more clearly worded definitions of certain terminology, would improve the quality and value of recommendations for future melanoma clinical practice guidelines, according to researchers.
Calming down immune cells could hold key to melanoma treatment
Immune cells may be responsible for drug resistance in melanoma patients, according to research published in Cancer Discovery.